Document Detail

Early anti-remodeling effect of labetalol in the congestive heart failure model induced by aortic constriction in the guinea pig.
MedLine Citation:
PMID:  11973419     Owner:  NLM     Status:  MEDLINE    
We investigated the effects of the beta1-beta2-alpha1-blocker, labetalol, in the congestive heart failure (CHF) model induced by aortic constriction in the guinea pig. One hundred days after aortic constriction, 52 animals were given either placebo, labetalol 2 mg/kg/d, or labetalol 20 mg/kg/d for 60 days. Eighteen sham-operated animals were used as controls. Investigations were performed at the end of the treatment period. Compared with sham-operated animals, banded animals receiving placebo showed signs of overt CHF with cardiac, systemic and regional (mesenteric and femoral) hemodynamic dysfunction, and pulmonary and hepatic congestion. An increase in whole heart, atria, and left and right ventricle weights associated with left ventricular cavity enlargement and left and right ventricular wall thickening indicated a remodeling process. Compared with placebo, labetalol did not significantly modify cardiac, systemic, or regional hemodynamic variables but significantly decreased pulmonary and hepatic congestion. Labetalol significantly reduced left ventricular cavity area (-10 and -20% after 2 and 20 mg/kg, respectively) and left ventricular (-4 and -16%) and right ventricular (-4 and -19%) wall thickness. In conclusion, labetalol induced partial regression of cardiac remodeling before hemodynamic improvement. This early anti-remodeling effect could play a role in the favorable effects observed with beta1-beta2-alpha1-blockers in humans.
Danielle Pape; Sonia Goineau; Pascal Guillo; Marie-Paule Ramée; Eric Bellissant
Related Documents :
9641329 - Partial left ventriculectomy and mitral valve repair for end-stage congestive heart fai...
11287899 - Right ventricular dysplasia in an asymptomatic young man: an uncommon case with biventr...
9881899 - Surgical successful treatment of cushing's syndrome in a pregnant patient complicated w...
23972409 - Illness perceptions, mood and quality of life: a systematic review of coronary heart di...
10373219 - Angiotensin-converting enzyme inhibition restores hepatocyte growth factor production i...
12638679 - Drug-induced toxic myocarditis.
19014709 - Resting myocardial perfusion quantification with cmr arterial spin labeling at 1.5 t an...
9534049 - Rited (registro italiano test eco-dobutamina): side effects and complications of echo-d...
6853899 - Effects of lidocaine and droxicainide on myocardial necrosis: a comparative study.
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  39     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2002 May 
Date Detail:
Created Date:  2002-04-25     Completed Date:  2002-09-16     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  746-53     Citation Subset:  IM    
Laboratoire de Pharmacologie Expérimentale et Clinique, UPRES EA 3194, Groupe de Recherche Cardio-Vasculaire, Faculté de Médecine, Rennes, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / pharmacology,  therapeutic use
Aorta / drug effects,  physiopathology
Aortic Valve Stenosis / drug therapy*,  pathology,  physiopathology
Body Weight / drug effects
Disease Models, Animal*
Guinea Pigs
Heart Failure / drug therapy*,  pathology,  physiopathology*
Hemodynamics / drug effects
Labetalol / pharmacology*,  therapeutic use
Organ Size / drug effects
Ventricular Remodeling / drug effects*
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 36894-69-6/Labetalol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Inhibition of vascular smooth muscle cell growth by angiotensin type 2 receptor stimulation for in v...
Next Document:  Intravenous adrenomedullin in myocardial function and energy metabolism in patients after myocardial...